ScripUS President Donald Trump’s ever-evolving stance on tariffs may be rattling the world and also has pharma on tenterhooks, but going down that path for generic medicines may be a doubled-edged sword or
Pink SheetUS President Donald Trump has announced a general 26% reciprocal tariff on India, but a country-agnostic exemption of categories like pharmaceuticals implies that Indian pharma firms will not be direc
ScripEli Lilly’s blockbuster obesity and type 2 diabetes therapy, Mounjaro (tirzepatide) has made its India debut throwing down the gauntlet to rival Novo Nordisk, currently in the wings with Wegovy (injec
ScripIndia’s top-ranked drug maker Sun Pharmaceutical Industries has signaled growing ambitions in the oncology-dermatological segment, snapping up the US immunotherapy and targeted oncology company Checkp